Stock ACXP ACURX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.51 USD -.--% Intraday chart for Acurx Pharmaceuticals, Inc. -.--% -34.46%
May. 15 Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection CI
May. 15 Transcript : Acurx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 15, 2024

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating
MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $14 From $13, Keeps Buy Rating
MT
Acurx Reports 96% Clinical Cure Rate in Phase 2 Trial of Ibezapolstat in C. Difficile Infection; Shares Fall
MT
Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection
CI
Maxim Raises Price Target on Acurx Pharmaceuticals to $10 From $7, Keeps Buy Rating
MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $13 From $14, Keeps Buy Rating
MT
HC Wainwright Initiates Acurx Pharmaceuticals With Buy Rating, Sets $14 Price Target
MT
Alliance Global Starts Acurx Pharmaceuticals at Buy With $14 Price Target
MT
Maxim Group Starts Acurx Pharmaceuticals at Buy With $12 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACXP Stock
  4. News Acurx Pharmaceuticals, Inc.
  5. Analyst Reco.